MACROGENICS, INC. Research and Development Expense
MACROGENICS, INC. (MGNX) reported Research and Development Expense of $38.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- MACROGENICS, INC. research and development expense for the quarter ending 2026-06-30 was $38.78M, a 4.93% decline year-over-year.
- MACROGENICS, INC. research and development expense for the quarter ending 2026-03-31 was $34.97M, a 11.90% decline year-over-year.
- MACROGENICS, INC. research and development expense for the quarter ending 2025-12-31 was $33.97M, a 12.64% decline year-over-year.
- MACROGENICS, INC. research and development expense for the quarter ending 2025-09-30 was $32.71M, a 19.32% decline year-over-year.
- MACROGENICS, INC. research and development expense for fiscal 2025 was $147.17M, a 16.94% decline from fiscal 2024.
- MACROGENICS, INC. research and development expense for fiscal 2024 was $177.19M, a 6.37% increase from fiscal 2023.
- MACROGENICS, INC. research and development expense for fiscal 2023 was $166.58M, a 19.54% decline from fiscal 2022.
- MACROGENICS, INC. research and development expense for fiscal 2022 was $207.03M, a 3.52% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.78M 10-Q · filed 2026-08-14 | $73.75M 10-Q · filed 2026-08-14 | $107.73M derived: sum of 3 quarters · filed 2026-08-14 | $140.44M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $34.97M 10-Q · filed 2026-05-13 | $68.95M derived: sum of 2 quarters · filed 2026-05-13 | $101.66M derived: sum of 3 quarters · filed 2026-05-13 | $142.45M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $33.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $66.68M derived: sum of 2 quarters · filed 2026-03-09 | $107.47M derived: sum of 3 quarters · filed 2026-08-14 | $147.17M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $32.71M 10-Q · filed 2025-11-12 | $73.50M derived: sum of 2 quarters · filed 2026-08-14 | $113.20M 10-Q · filed 2025-11-12 | $152.09M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $40.79M 10-Q · filed 2026-08-14 | $80.49M 10-Q · filed 2026-08-14 | $119.38M derived: sum of 3 quarters · filed 2026-08-14 | $159.92M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $39.70M 10-Q · filed 2026-05-13 | $78.59M derived: sum of 2 quarters · filed 2026-05-13 | $119.13M derived: sum of 3 quarters · filed 2026-05-13 | $170.86M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $38.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $79.43M derived: sum of 2 quarters · filed 2026-03-09 | $131.16M derived: sum of 3 quarters · filed 2026-03-09 | $177.19M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $40.54M 10-Q · filed 2025-11-12 | $92.28M derived: sum of 2 quarters · filed 2025-11-12 | $138.30M 10-Q · filed 2025-11-12 | $185.66M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-06-30 | $51.73M 10-Q · filed 2025-08-14 | $97.76M 10-Q · filed 2025-08-14 | $145.11M derived: sum of 3 quarters · filed 2026-03-09 | $175.24M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-03-31 | $46.03M 10-Q · filed 2025-05-13 | $93.38M derived: sum of 2 quarters · filed 2026-03-09 | $123.51M derived: sum of 3 quarters · filed 2026-03-09 | $166.74M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2023-12-31 | $47.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $77.48M derived: sum of 2 quarters · filed 2026-03-09 | $120.71M derived: sum of 3 quarters · filed 2026-03-09 | $166.58M 10-K · filed 2026-03-09 | |||
| 2023-09-30 | $30.13M 10-Q · filed 2024-11-05 | $73.36M derived: sum of 2 quarters · filed 2024-11-05 | $119.23M 10-Q · filed 2024-11-05 | $164.89M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-06-30 | $43.23M 10-Q · filed 2024-08-06 | $89.10M 10-Q · filed 2024-08-06 | $134.75M derived: sum of 3 quarters · filed 2025-03-20 | $182.95M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-03-31 | $45.87M 10-Q · filed 2024-05-09 | $91.53M derived: sum of 2 quarters · filed 2025-03-20 | $139.72M derived: sum of 3 quarters · filed 2025-03-20 | $191.46M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $45.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $93.84M derived: sum of 2 quarters · filed 2025-03-20 | $145.59M derived: sum of 3 quarters · filed 2025-03-20 | $207.03M 10-K · filed 2025-03-20 | |||
| 2022-09-30 | $48.19M 10-Q · filed 2023-11-06 | $99.94M derived: sum of 2 quarters · filed 2023-11-06 | $161.37M 10-Q · filed 2023-11-06 | $161.37M 10-Q · filed 2022-11-03 | $217.23M derived: sum of 4 quarters · filed 2024-03-07 | ||
| 2022-06-30 | $51.74M 10-Q · filed 2023-08-09 | $113.18M 10-Q · filed 2023-08-09 | $169.03M derived: sum of 3 quarters · filed 2024-03-07 | $218.86M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-03-31 | $61.44M 10-Q · filed 2023-05-09 | $117.29M derived: sum of 2 quarters · filed 2024-03-07 | $167.11M derived: sum of 3 quarters · filed 2024-03-07 | $222.89M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2021-12-31 | $55.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $105.68M derived: sum of 2 quarters · filed 2024-03-07 | $161.46M derived: sum of 3 quarters · filed 2024-03-07 | $214.58M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $49.82M 10-Q · filed 2022-11-03 | $105.60M derived: sum of 2 quarters · filed 2022-11-03 | $158.72M 10-Q · filed 2022-11-03 | $201.02M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-06-30 | $55.78M 10-Q · filed 2022-08-08 | $108.90M 10-Q · filed 2022-08-08 | $151.20M derived: sum of 3 quarters · filed 2023-03-15 | $195.86M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-03-31 | $53.12M 10-Q · filed 2022-05-03 | $95.42M derived: sum of 2 quarters · filed 2023-03-15 | $140.08M derived: sum of 3 quarters · filed 2023-03-15 | $197.43M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2020-12-31 | $42.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $86.96M derived: sum of 2 quarters · filed 2023-03-15 | $144.31M derived: sum of 3 quarters · filed 2023-03-15 | $193.20M 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $44.66M 10-Q · filed 2021-11-02 | $102.01M derived: sum of 2 quarters · filed 2021-11-02 | $150.90M 10-Q · filed 2021-11-02 | $202.86M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | $57.35M 10-Q · filed 2021-07-29 | $106.25M 10-Q · filed 2021-07-29 | $158.20M derived: sum of 3 quarters · filed 2022-02-24 | $203.05M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | $48.89M 10-Q · filed 2021-04-29 | $100.85M derived: sum of 2 quarters · filed 2022-02-24 | $145.70M derived: sum of 3 quarters · filed 2022-02-24 | $197.14M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $51.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $96.81M derived: sum of 2 quarters · filed 2022-02-24 | $148.25M derived: sum of 3 quarters · filed 2022-02-24 | $195.31M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $44.85M 10-Q · filed 2020-11-04 | $96.29M derived: sum of 2 quarters · filed 2020-11-04 | $143.35M 10-Q · filed 2020-11-04 | $190.28M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $51.44M 10-Q · filed 2020-07-31 | $98.50M 10-Q · filed 2020-07-31 | $145.43M derived: sum of 3 quarters · filed 2021-02-25 | $191.64M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $47.06M 10-Q · filed 2020-05-05 | $93.98M derived: sum of 2 quarters · filed 2021-02-25 | $140.20M derived: sum of 3 quarters · filed 2021-02-25 | $192.22M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $46.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $93.14M derived: sum of 2 quarters · filed 2021-02-25 | $145.16M derived: sum of 3 quarters · filed 2021-02-25 | $190.83M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $46.22M 10-Q · filed 2019-11-06 | $98.23M derived: sum of 2 quarters · filed 2019-11-06 | $143.90M 10-Q · filed 2019-11-06 | $182.89M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $52.01M 10-Q · filed 2019-07-31 | $97.68M 10-Q · filed 2019-07-31 | $136.67M derived: sum of 3 quarters · filed 2020-02-25 | $177.65M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $45.67M 10-Q · filed 2019-05-01 | $84.66M derived: sum of 2 quarters · filed 2020-02-25 | $125.64M derived: sum of 3 quarters · filed 2020-02-25 | $160.10M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $38.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $79.97M derived: sum of 2 quarters · filed 2020-02-25 | $114.43M derived: sum of 3 quarters · filed 2020-02-25 | $147.23M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $40.98M 10-Q · filed 2018-11-07 | $75.44M derived: sum of 2 quarters · filed 2018-11-07 | $108.25M 10-Q · filed 2018-11-07 | $139.35M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $34.46M 10-Q · filed 2018-08-07 | $67.26M 10-Q · filed 2018-08-07 | $98.37M derived: sum of 3 quarters · filed 2019-02-26 | $128.67M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $32.80M 10-Q · filed 2018-05-07 | $63.91M derived: sum of 2 quarters · filed 2019-02-26 | $94.21M derived: sum of 3 quarters · filed 2019-02-26 | $127.55M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $31.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $61.41M derived: sum of 2 quarters · filed 2019-02-26 | $94.75M derived: sum of 3 quarters · filed 2019-02-26 | $122.09M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $30.30M 10-Q · filed 2017-11-08 | $63.64M derived: sum of 2 quarters · filed 2017-11-08 | $90.98M 10-Q · filed 2017-11-08 | $121.03M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $33.34M 10-Q · filed 2017-08-02 | $60.69M 10-Q · filed 2017-08-02 | $90.73M derived: sum of 3 quarters · filed 2018-02-27 | $114.83M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $27.35M 10-Q · filed 2017-05-03 | $57.39M derived: sum of 2 quarters · filed 2018-02-27 | $81.49M derived: sum of 3 quarters · filed 2018-02-27 | $104.15M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $30.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $54.15M derived: sum of 2 quarters · filed 2018-02-27 | $76.81M derived: sum of 3 quarters · filed 2018-02-27 | $98.27M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $24.10M 10-Q · filed 2016-11-02 | $46.76M derived: sum of 2 quarters · filed 2016-11-02 | $68.23M 10-Q · filed 2016-11-02 | $87.88M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $22.66M 10-Q · filed 2016-08-03 | $44.12M 10-Q · filed 2016-08-03 | $63.77M derived: sum of 3 quarters · filed 2017-02-28 | $82.41M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $21.46M 10-Q · filed 2016-05-04 | $41.11M derived: sum of 2 quarters · filed 2017-02-28 | $59.75M derived: sum of 3 quarters · filed 2017-02-28 | $77.08M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $19.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $38.28M derived: sum of 2 quarters · filed 2017-02-28 | $55.62M derived: sum of 3 quarters · filed 2017-02-28 | $70.19M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $18.63M 10-Q · filed 2015-11-04 | $35.97M derived: sum of 2 quarters · filed 2015-11-04 | $50.54M 10-Q · filed 2015-11-04 | $64.88M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $17.34M 10-Q · filed 2015-08-05 | $31.90M 10-Q · filed 2015-08-05 | $46.25M derived: sum of 3 quarters · filed 2016-02-29 | $57.34M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $14.57M 10-Q · filed 2015-05-06 | $14.57M 10-Q · filed 2014-05-06 | $28.92M derived: sum of 2 quarters · filed 2016-02-29 | $40.01M derived: sum of 3 quarters · filed 2016-02-29 | $51.05M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $14.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $25.44M derived: sum of 2 quarters · filed 2016-02-29 | $36.48M derived: sum of 3 quarters · filed 2016-02-29 | $46.58M 10-K · filed 2016-02-29 | $46.58M 10-K · filed 2014-03-20 | ||
| 2013-09-30 | $11.09M 10-Q · filed 2014-11-12 | $11.09M 10-Q · filed 2013-11-12 | $22.14M derived: sum of 2 quarters · filed 2014-11-12 | $32.23M 10-Q · filed 2014-11-12 | $32.23M 10-Q · filed 2013-11-12 | $40.74M derived: sum of 4 quarters · filed 2015-03-03 | |
| 2013-06-30 | $11.05M 10-Q · filed 2014-08-05 | $21.15M 10-Q · filed 2014-08-05 | $29.65M derived: sum of 3 quarters · filed 2015-03-03 | $41.62M derived: sum of 4 quarters · filed 2015-03-03 | |||
| 2013-03-31 | $10.10M 10-Q · filed 2014-05-06 | $18.60M derived: sum of 2 quarters · filed 2015-03-03 | $30.57M derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2012-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $20.48M derived: sum of 2 quarters · filed 2015-03-03 | $45.43M 10-K · filed 2015-03-03 | $45.43M 10-K · filed 2014-03-20 | |||
| 2012-09-30 | $11.97M 10-Q · filed 2013-11-12 | $36.92M 10-Q · filed 2013-11-12 | |||||
| 2011-12-31 | $41.09M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |